Nexletol is not a statin. It belongs to a different class of cholesterol-lowering medication, and it works through a distinct biochemical pathway. The active ingredient, bempedoic acid, was specifically developed as an alternative for people who can’t tolerate statins or need additional LDL cholesterol reduction beyond what statins alone can achieve.
How Nexletol Works Differently
Statins lower cholesterol by blocking an enzyme called HMG-CoA reductase, which is active throughout the body, including in muscle tissue. Nexletol targets a different enzyme further upstream in the same cholesterol-production chain: ATP-citrate lyase (ACL). The end result is similar. Your liver produces less cholesterol, ramps up its LDL receptors, and pulls more “bad” cholesterol out of your bloodstream.
The key distinction is where the drug becomes active. Nexletol is a prodrug, meaning it’s inactive when you swallow it and only “switches on” inside liver and kidney cells. It does not activate in muscle cells or fat tissue. Statins, by contrast, are active throughout the body, which is why muscle pain and weakness are their most common complaints. In phase 3 clinical trials, muscle-related side effects with Nexletol were not statistically different from placebo.
Who Nexletol Is Designed For
The FDA approved Nexletol for two main groups. The first is adults with established cardiovascular disease, or those at high risk for a cardiovascular event, who are unable to take the recommended statin dose. The second is adults with primary hyperlipidemia (including the inherited form called heterozygous familial hypercholesterolemia) who need additional LDL lowering on top of diet and other therapies.
To be classified as statin-intolerant, most guidelines require that you’ve tried at least two different statins, including one at its lowest approved dose, and experienced side effects that improved or resolved when the medication was stopped. If that describes your situation, Nexletol is one of the non-statin options your doctor can consider.
How Much It Lowers LDL Cholesterol
On its own or added to other lipid-lowering therapies, Nexletol reduced LDL cholesterol by about 20% compared to placebo over six months in FDA-reviewed trials. That’s less than the 30% to 50% reduction you’d typically see with moderate- to high-intensity statin therapy, but it’s a meaningful drop for someone who can’t take statins at all.
When combined with ezetimibe (a drug that blocks cholesterol absorption in the gut), the pair lowered LDL by roughly 39% in patients with type 2 diabetes who were not on a statin. That combination is sold as a single tablet under the brand name Nexlizet. For comparison, ezetimibe alone lowered LDL by about 19% in the same trial, so the combination nearly doubled the benefit.
Using Nexletol Alongside a Statin
Even though Nexletol isn’t a statin, some people take both. If you can tolerate a low statin dose but can’t reach your cholesterol goal, adding Nexletol can provide extra reduction. There are limits, though. If you’re on simvastatin, the dose should stay at 20 mg or below while taking Nexletol, because the combination raises simvastatin levels in your blood and increases the risk of muscle problems. Pravastatin should be kept at 40 mg or below for the same reason.
These interactions don’t apply to all statins, just those two. But it’s a good reminder that even a non-statin cholesterol drug can interact with statins in ways that matter.
Side Effects Compared to Statins
The biggest practical advantage of Nexletol over statins is its muscle safety profile. Because the drug isn’t activated in muscle tissue, the rates of muscle weakness, pain, and spasms in clinical trials matched what patients on a placebo experienced. That’s a significant difference from statins, where muscle complaints affect an estimated 5% to 20% of users depending on the study and statin type.
Nexletol does carry its own set of potential side effects. Elevated uric acid levels are one, which can trigger gout flares in people who are predisposed. It can also raise creatinine (a marker of kidney function) and cause tendon problems in rare cases. These are distinct from the side-effect profile of statins, so the tradeoffs look different for each person.
Beyond Cholesterol: Cardiovascular Protection
One question with any cholesterol drug is whether lowering the number actually prevents heart attacks and strokes. The FDA’s 2024 labeling update for Nexletol specifically includes reducing the risk of heart attack and the need for coronary procedures in adults who can’t take recommended statin therapy. This makes it one of the few non-statin cholesterol drugs with a cardiovascular outcomes indication, not just a cholesterol-lowering one.